90: Metformin, Berberine, Dihydroberberine: Which One Is Best?

In this episode Dr. Shawn Tassone discusses the use of metformin, berberine, and dihydroberberine for weight loss in women, particularly those in perimenopause and menopause. He explains that while GLP-1 medications like Ozempic and Monjaro are effective for weight loss, some women may prefer to try metformin, berberine, or dihydroberberine due to concerns or fear of injectable medications. He provides an overview of each medication, including their uses, dosages, side effects, and cost. Dr. Tassone also discusses the differences between berberine and dihydroberberine, and why he prefers dihydroberberine for weight loss. He also emphasizes the importance of consulting with a doctor and monitoring labs while using these medications. Episode Highlights Why Metformin, berberine, and dihydroberberine are medications/supplements that can be used for weight loss Why some women may prefer to try metformin, berberine, or dihydroberberine How Metformin can be beneficial for women with polycystic ovarian syndrome. Benefits of Berberine The difference between Berberine and Dihydroberberine The importance of consulting with a doctor, monitoring labs, and cycling off these medications/supplements periodically. Cost difference between Metformin, berberine and dihydroberberine How personal preference plays a role in choosing between metformin, berberine, and dihydroberberine for weight loss Why you should avoid supplements advertised as similar to GLP-1 medications Resources Dr. Shawn Tassone's Practice | Tassone Advanced Gynecology Dr. Shawn Tassone's Book | Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormonal Archetype Quiz Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

There are no comments yet.

Please log in to write the first comment.